The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Valeant Pharmaceuticals International Inc

NYSE: VRX
Last

(U.S.) $20.39

Today's change+0.25 +1.24%
Updated July 1 3:44 PM EDT. Delayed by at least 15 minutes.
 

Valeant Pharmaceuticals International Inc

NYSE: VRX
Last

(U.S.) $20.39

Today's change+0.25 +1.24%
Updated July 1 3:44 PM EDT. Delayed by at least 15 minutes.

Valeant Pharmaceuticals International Inc up (U.S.)$0.25

Valeant Pharmaceuticals International Inc is up today by (U.S.)$0.25 or 1.24% to (U.S.)$20.39. Over the last five days, shares have gained 0.59%, but are down 79.94% for the last year to date. Shares have underperformed the S&P 500 by 92.33% during the last year.

Key company metrics

  • Open(U.S.) $20.40
  • Previous close(U.S.) $20.14
  • High(U.S.) $21.65
  • Low(U.S.) $19.83
  • Bid / Ask(U.S.) $20.38 / (U.S.) $20.39
  • YTD % change-79.94%
  • Volume29,383,034
  • Average volume (10-day)22,454,989
  • Average volume (1-month)27,623,660
  • Average volume (3-month)31,928,599
  • 52-week range(U.S.) $18.55 to (U.S.) $263.81
  • Beta0.27
  • Trailing P/ENegative, not meaningful
  • P/E 1 year forward3.04×
  • Forward PEG0.39×
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) -$2.14
Updated July 1 3:44 PM EDT. Delayed by at least 15 minutes.
S&P TSX0.20%Sector:Industry:

Latest Company News

View more News
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q1/2016Q4/2015Q3/2015Q2/2015
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedMar 31, 201603/31/2016Dec 31, 201512/31/2015Sep 30, 201509/30/2015Jun 30, 201506/30/2015
Revenue2,3722,7362,7872,732
Total other revenue--------
Total revenue2,3722,7362,7872,732
Gross profit1,7422,0602,1392,047
Total cost of revenue630677648685
Total operating expense2,3052,5422,3392,391
Selling / general / administrative813743698686
Research & development1039610281
Depreciation / amortization695789679585
Interest expense (income), net operating--------
Unusual expense (income)42195182177
Other operating expenses, total234330177
Operating income66195448342
Interest income (expense), net non-operating-427-433-420-413
Gain (loss) on sale of assets--------
Other--------
Income before tax-366-240-6-65
Income after tax-373-36252-52
Income tax, total7122-57-13
Net income-374-36250-53
Total adjustments to net income--------
Net income before extra. items-374-36250-53
Minority interest-11-2-1
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items-374-36250-53
Inc. avail. to common incl. extra. items-374-36250-53
Diluted net income-374-36250-53
Dilution adjustment----00
Diluted weighted average shares345348351344
Diluted EPS excluding extraordinary itemsvalue per share-1.08-1.040.14-0.15
Dividends per sharevalue per share0.000.000.000.00
Diluted normalized EPSvalue per share-1.00-0.540.570.19